Claims
- 1. A compound of the formula (I): ##STR93## wherein: A is an 8-, 9- or 10-membered bicyclic heteroaryl, a 5- or 6-membered heteroaryl, naphthyl or phenyl, or any of the foregoing substituted with E where E is selected from the group consisting of C.sub.1 -C.sub.6 -alkyl, mono- or di-substituted C.sub.1 --C.sub.6 -alkyl (where the substituent is independently selected from hydroxy, amino, halo, nitro, C.sub.1 -C.sub.4 -alkyl-S(O).sub.p -, C.sub.1 -C.sub.4 -alkoxy, phenyl-S(O).sub.p -, or cyano), halo, trifluoromethyl, nitro, hydroxy, amino, C.sub.1 -C.sub.4 -alkylamino, di-C.sub.1 -C.sub.4 -alkylamino, cyano, C.sub.1 C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl-S(O).sub.p -, phenyl-S(O).sub.p -, carbamoyl, C.sub.2 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -alkynyl, C.sub.3 -C.sub.7 -cycloalkyl, C.sub.3 -C.sub.7 -cycloalkyl-C.sub.1 -C.sub.3 -alkyl, C.sub.3 -C.sub.7 -cycloalkyl-C.sub.2 -C.sub.3 -alkenyl, C.sub.3 -C.sub.7 -cycloalkyl-C.sub.2 -C.sub.3 -alkynyl, C.sub.1 -C4-alkoxycarbonylamino, C.sub.1 -C4-alkanoylamino, C.sub.1 -C4-alkanoyl-(N-C.sub.1 -C.sub.4 -alkyl)amino, C.sub.1 -C4-alkanesulphonamido, benzenesulphonamido, aminosulphonyl, C.sub.1 -C.sub.4 -alkylaminosulphonyl, di-C.sub.1 C.sub.4 -alkyl-aminosulphonyl, C.sub.1 -C.sub.4 -alkoxycarbonyl, C.sub.2 -C.sub.4 -alkanoyloxy, formyl-C.sub.1 -C.sub.4 -alkyl, trifluoro-C.sub.1 -C.sub.3 -alkylsulphonyl, hydroxyimino-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.4 -alkoxyimino-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.6 -alkylcarbamoylamino, phenyl, C.sub.1 -C.sub.4 -alkylcarbamoyl and di-C.sub.1 -C.sub.4 -alkyl-carbamoyl; provided that if A is a ring structure, the --OCH(R.sup.3)- and -X- linking groups are positioned in a 1,2 relationship to one another on ring carbon atoms of A, wherein p is 0, 1 or 2;
- B is phenyl or a 5- or 6-membered heteroaryl ring, or either of the foregoing substituted with G, where G is selected from the group consisting of halo, trifluoromethyl, nitro, hydroxy, C.sub.1 -C.sub.6 -alkyl, C.sub.3 -C.sub.7 -cycloalkyl, C.sub.3 -C.sub.7 -cycloalkyl-C.sub.1 -C.sub.3 -alkyl, amino, C.sub.1 -C.sub.4 -alkylamino, di-C.sub.1 -C.sub.4 -alkyl-amino, cyano, -S(O).sub.p -C.sub.1 -C.sub.6 -alkyl, carbamoyl, C.sub.1 -C.sub.4 -alkylcarbamoyl and di-C.sub.1 -C.sub.4 -alkyl-carbamoyl;
- D is pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, thienyl, furyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl or phenyl, or any of the foregoing mono- or di-substituted with halo, trifluoromethyl, nitro, hydroxy, amino, C.sub.1 -C.sub.4 -alkylamino, di-C.sub.1 -C.sub.4 -alkyl-amino, cyano, C.sub.1 -C.sub.6 -alkoxy, --S(O).sub.p -C.sub.1 -C.sub.4 -alkyl, --S(O).sub.p -phenyl, C .sub.1 -C.sub.4 -alkanoyl, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkyl mono-substituted with hydroxy, halo, nitro, cyano or amino;
- R.sup.1 is carboxy, carboxy-C.sub.1 -C.sub.3 -alkyl, tetrazolyl, tetrazolyl-C.sub.1 -C.sub.3 -alkyl, tetronic acid, hydroxamic acid, sulphonic acid, or
- R.sup.1 is of the formula -CONR.sup.a R.sup.a1 :
- where R.sup.a is hydrogen or C.sub.1 -C.sub.6 -alkyl, and R.sup.a1 is J or hydrogen, where J is selected from C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -alkynyl, C.sub.3 -C.sub.7 -cycloalkyl, C.sub.3 -C.sub.7 -cycloalkyl-C.sub.1 -C.sub.6 -alkyl, C.sub.3 -C.sub.7 -cycloalkyl-C.sub.2 -C.sub.6 -alkenyl, C.sub.3 -C.sub.7 -cycloalkyl-C.sub.2 -C.sub.6 -alkynyl, C.sub.5 -C.sub.7 -cycloalkenyl, C.sub.5 -C.sub.7 -cycloalkenyl-C.sub.1 -C.sub.6 -alkyl, C.sub.5 -C.sub.7 -cycloalkenyl-C.sub.2 -C.sub.6 -alkenyl, C.sub.5 -C.sub.7 -cycloalkenyl-C.sub.2 -C.sub.6 -alkynyl, or R.sup.a1 is J mono-substituted with a 5- or 6-membered saturated or partially-saturated heterocyclic ring, a 5- or 6-membered heteroaryl ring or a 5- or 6-membered heteroaryl-C.sub.1 -C.sub.3 -alkyl; or
- where R.sup.a and R.sup.a1 together with the nitrogen to which they are attached form a group having the formula --NH--CH(R.sup.C)--COOR.sup.D wherein R.sup.C is hydrogen, C.sub.1 -C.sub.6 -alkyl, C.sub.2 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -alkynyl, phenyl, phenyl(C.sub.1 -C.sub.3 -alkyl), 5- or 6-membered heteroaryl or 5- or 6-membered heteroaryl(C.sub.1 -C.sub.3 -alkyl) and R.sup.D is H or C.sub.1 -C.sub.6 -alkyl, wherein any alkyl, alkenyl, alkynyl, phenyl or heteroaryl group of the foregoing is either unsubstituted or mono- substituted with E;
- R.sup.1 is of the formula --CONHSO.sub.2 J;
- X is of the formula --(CHR.sup.4).sub.n -- or --(CHR.sup.4).sub.r CR.sup.4 .dbd.CR.sup.4 (CHR.sup.4).sub.q --, where n is 1, 2 or 3; and r and q are either both 0, or r is 0 and q is 1, or r is 1 and q is 0; and
- R.sup.3 and R.sup.4 are independently selected from hydrogen or C.sub.1 -C.sub.4 -alkyl; wherein:
- when B is a 6-membered ring, R.sup.1 is positioned on ring B in a 1,3 or a 1,4 relationship with the --OCH(R.sup.3)-- linking group, or
- when B is a 5-membered ring, R.sup.1 is positioned in a 1,3 relationship with the --OCH(R.sup.3)-- linking group;
- or an N-oxide of any of the foregoing compounds;
- or any of the foregoing compounds having S-oxides of sulphur containing rings therein;
- or a pharmaceutically-acceptable salt or an in vivo hydrolysable ester or amide of any of the foregoing compounds;
- provided the compound of formula (I) is not 4-(2-benzyl-3-hydroxy-4-formylphenoxymethyl)-3-methoxybenzoic acid, or 4-(2-(3-phenylprop-2-en-1-yl)-3-hydroxy-4-formylphenoxymethyl)-3-methoxybenzoic acid.
- 2. A compound according to claim 1, wherein A is phenyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thienyl or 1,2,3-thiadiazolyl or any of the foregoing mono- or di-substituted with E.
- 3. A compound according to claim 1, wherein B is phenyl, pyridyl, thiazolyl, thienyl, thiadiazolyl, pyrazinyl, pyridazinyl or pyrimidyl or any of the foregoing mono- or di-substituted with G.
- 4. A compound according to claim 1, wherein D is phenyl or phenyl mono- or di-substituted with halo, trifluoromethyl, nitro, hydroxy, amino, C.sub.1 C.sub.4 -alkylamino, di-C.sub.1 -C.sub.4 -alkylamino, cyano, C.sub.1 C.sub.6 -alkoxy, -S(O).sub.p -C.sub.1 -C.sub.4 -alkyl, -S(O).sub.p -phenyl, C.sub.1 -C.sub.4 -alkanoyl, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.4 -alkyl mono- or di-substituted with hydroxy, halo, nitro, cyano or amino.
- 5. A compound according to claim 1, having the formula (V). ##STR94## wherein: X is --(CH.sub.2).sub.2 -- or --CH.dbd.CH--;
- B is phenyl, thiadiazolyl or pyridyl; and
- R.sup.6 is hydrogen, halo, trifluoromethyl, nitro, hydroxy, amino, cyano, C.sub.1 -C.sub.6 -alkoxy, C.sub.1 -C.sub.6 -alkyl-S(O).sub.p, phenyl-S(O).sub.p, C.sub.1 -C.sub.6 -alkyl mono- or di-substituted by hydroxy, amino, halo, nitro or cyano, C.sub.3 -C.sub.7 -cycloalkyl, C.sub.3 -C.sub.7 -cycloalkyl-C.sub.1 -C.sub.3 -alkyl, carbamoyl, C.sub.1 -C.sub.4 -alkylcarbamoyl, di-C.sub.1 -C.sub.4 -alkyl-carbamoyl, C.sub.2 -C.sub.6 -alkenyl, C.sub.2 -C.sub.6 -alkynyl, C.sub.1 -C.sub.4 -alkoxycarbonylamino, C.sub.1 -C.sub.4 -alkanoylamino, C.sub.1 -C.sub.4 -alkanoyl(N-C.sub.1 -C.sub.4 -alkyl)amino, C.sub.1 -C.sub.4 -alkanesulphonamido, benzenesulphonamido, aminosulphonyl, C.sub.1 -C.sub.4 -alkylaminosulphonyl, di-C.sub.1 -C.sub.4 -alkyl-aminosulphonyl, C.sub.1 -C.sub.4 -alkoxycarbonyl, C.sub.2 -C.sub.4 -alkanoyloxy, C.sub.1 -C.sub.6 -alkanoyl, formyl-C.sub.1 -C.sub.4 -alkyl, trifluoro-C.sub.1 -C.sub.3 -alkylsulphonyl, hydroxyimino-C.sub.1 -C.sub.6 -alkyl, C.sub.1 -C.sub.4 -alkoxyimino-C.sub.1 -C.sub.6 -alkyl or C.sub.1 -C.sub.6 -alkylcarbamoylamino.
- 6. A compound according to claim 1, selected from the group consisting of:
- 4-[6-bromo-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[5-nitro-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[4-chloro-6-methyl-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[5-bromo-6-cyano-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[5-chloro-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[4-cyanomethyl-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[6-bromo-2-(phenethyl)phenoxymethyl]-2-hydroxybenzoic acid;
- 4-[5-methyl-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[2-(phenethyl)-6-phenylphenoxymethyl]benzoic acid;
- 4- [6-amino-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4- [6-methanethio-2-(phenethyl )phenoxymethyl]benzoic acid;
- 4-[4-(1-(hydroxyimino)ethyl)-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[4-methyl-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[4-bromo-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[4-methoxy-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[6-cyano-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[6-cyano-4-methyl-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[4-chloro-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[6-benzenesulphonylmethyl-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[4-methanethio-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[5-bromo-2-(phenethyl)phenoxymethyl]benzoic acid;
- 4-[6-isopropyl-2-(phenethyl)phenoxymethyl]benzoic acid;
- 5- [4-(2-(phenethyl)-6-phenylphenoxymethyl)phenyl]tetrazole;
- 5- [4-(4-hydroxy-2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
- 5-[4-(4-methoxy-2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
- 5- [4-(2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
- 5- [4-(4-chloro-2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
- 5-[4-(4-bromo-2-(phenethyl)phenoxymethyl)phenyl]tetrazole;
- 5-[4-(6-bromo-2-(phenethyl)phenoxymethyl)phenyl]tetrazole; and
- 5-[4-(6-isopropyl-2-(phenethyl)phenoxymethyl)phenyl]tetrazole, or
- a pharmaceutically-acceptable salt or an in vivo hydrolysable ester or amide of any of the foregoing compounds.
- 7. A pharmaceutical composition which comprises a compound according to claim 1 and a pharmaceutically-acceptable excipient or diluent.
- 8. A method of relieving pain in a patient suffering therefrom, said method comprising administering a therapeutically effective amount of compound according to claim 1.
- 9. A process for preparing a compound of formula (I) according to claim 1, said process comprising:
- ia) when X is --(CHR.sup.4).sub.n --, and n is 2 or 3, reducing a compound of formula: ##STR95## ib) when X is -(CHR.sup.4).sub.n - and n is 1, 2 or 3, reacting a compound of formula: ##STR96## with a compound of formula:
- L--CH(R.sup.3)--B--R.sup.1
- wherein L is a leaving group; or
- ic) when A is an activated heterocyclic ring, reacting a compound of formula: ##STR97## with a compound of formula: ##STR98## where, in any of the foregoing steps, ia), ib) or ic), any of A, B, D, X, R.sup.1, R.sup.3 and R.sup.4 bear protective groups when necessary;
- ii) removing any of said protecting groups; and
- iii) forming a pharmaceutically-acceptable salt of any of the foregoing compounds.
- 10. A process according to step ia), ib) or ic) of claim 9, for preparing a compound having the formula (V): ##STR99##
Priority Claims (1)
Number |
Date |
Country |
Kind |
9417532 |
Aug 1994 |
GBX |
|
Parent Case Info
This application is a national stage filing under 35 U.S.C. .sctn.371 of PCT/GB95/02030, filed Aug. 29, 1995.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/GB95/02030 |
8/29/1995 |
|
|
2/21/1997 |
2/21/1997 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO96/06822 |
3/7/1996 |
|
|
US Referenced Citations (21)
Foreign Referenced Citations (17)
Number |
Date |
Country |
2111035 |
Jun 1994 |
CAX |
0122321 |
Oct 1984 |
EPX |
0193822 |
Sep 1986 |
EPX |
0200101 |
Dec 1986 |
EPX |
0218077 |
Apr 1987 |
EPX |
0534667 |
Mar 1991 |
EPX |
0475206 |
Mar 1992 |
EPX |
0480641 |
Apr 1992 |
EPX |
0752421 |
Jan 1997 |
EPX |
1560281 |
Feb 1980 |
GBX |
2041363 |
Sep 1986 |
GBX |
9220642 |
Nov 1992 |
WOX |
9603380 |
Feb 1996 |
WOX |
9606822 |
Mar 1996 |
WOX |
9611902 |
Apr 1996 |
WOX |
9700863 |
Jan 1997 |
WOX |
9700864 |
Jan 1997 |
WOX |
Non-Patent Literature Citations (2)
Entry |
Derwent Patent Abstract of DE 2,701,854 (Abstract No. 52629Y/30). Wieckmann et al. |
Brown et al., J. Med. Chem 1989, 32, 807-826. |